Therapeutic revolution in the management of metastatic prostate cancer
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
La publicación se distribuye bajo la Licencia Creative Commons Atribución- 4.0 Internacional (CC BY 4.0). Los derechos de los trabajos publicados en esta revista son propiedad del autor, los cuales son libres de distribuir y difundir las mismas, siempre que cite correctamente la fuente.
Main Article Content
Abstract
not applicable
References
Armstrong, A.J., Szmulewitz, R.Z., Petrylak, D.P., Holzbeierlein, J., Villers, A., Azad, A. et al. (2019)‘ARCHES: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer’, Journal of Clinical Oncology, 37(32), pp. 2974–2986. https://doi.org/10.1200/JCO.19.00799.
Bahmad, H. (2023) Therapy Resistance in Prostate Cancer: Mechanisms and Insights. Elsevier. Chi, K.N., Agarwal, N., Bjartell, A., Chung, B.H., Pereira de Santana Gomes, A.J., Given, R. et al. (2019) ‘Apalutamide for metastatic, castration-sensitive prostate cancer’, New England Journal of Medicine, 381(1), pp. 13–24. https://doi.org/10.1056/NEJMoa1903307.
Desai, M.M., Cacciamani, G.E., Gill, K., Zhang, J., Liu, L., Abreu, A. et al. (2022) ‘Trends in incidence of metastatic prostate cancer in the US’, JAMA Network Open, 5(3), e222246.
Fizazi, K., Foulon, S., Carles, J., Roubaud, G., McDermott, R., Fléchon, A. et al. (2022) ‘Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2×2 factorial design’, Lancet, 399(10336), pp. 1695–1707. https://doi.org/10.1016/S0140-6736(22)00367-1.
Fizazi, K., Tran, N., Fein, L., Matsubara, N., Rodriguez-Antolin, A., Alekseev, B.Y. et al. (2019) ‘Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial’, Lancet Oncology, 20(5), pp. 686–700. https://doi.org/10.1016/S1470-2045(19)30082-8.
Hussain, M., Tombal, B., Saad, F., Fizazi, K., Sternberg, C.N., Crawford, E.D. et al. (2023) ‘Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the Phase III ARASENS trial’, Journal of Clinical Oncology, 41(20), pp. 3595–3607.
International Agency for Research on Cancer (2022) GLOBOCAN 2022: Cancer incidence, mortality and prevalence worldwide. World Health Organization. Disponible en: https://gco.iarc.fr/
Ministerio de Salud (2020) Guía de Práctica Clínica: Cáncer de Próstata en personas de 15 años y más. Chile: MINSAL.
Shalata, W., Gothelf, I., Bernstine, T., Michlin, R., Tourkey, L., Shalata, S. and Yakobson, A. (2024) ‘Mental health challenges in cancer patients: A cross-sectional analysis of depression and anxiety’, Cancers, 16(16), 2827. https://doi.org/10.3390/cancers16162827
Smith, M.R., Hussain, M., Saad, F., Fizazi, K., Sternberg, C.N., Crawford, D. et al. (2022) ‘Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial’, Future Oncology, 18(21), pp. 2585–2597.
Sweeney, C.J., Chen, Y.H., Carducci, M., Liu, G., Jarrard, D.F., Eisenberger, M. et al. (2015) ‘Chemohormonal therapy in metastatic hormone-sensitive prostate cancer’, New England Journal of Medicine, 373(8), pp. 737–746. https://doi.org/10.1056/NEJMoa1503747.